Patents by Inventor Felix Hartlepp

Felix Hartlepp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20240336701
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 10, 2024
    Inventors: Michael DIDONATO, Christoph ERKEL, Anna Galkin, Scott Martin GLASER, Klaus Felix HARTLEPP, Yong JIA, Alexandra KRAUS, Christian Cho-Hua LEE, Sarah Michelle RUE, Jian SHI, Xenia Karola WEZLER
  • ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
    Patent number: 11939397
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
  • REVERSAL BINDING AGENTS FOR ANTI-NATRIURETIC PEPTIDE RECEPTOR I (NPRI) ANTIBODIES AND USES THEREOF
    Publication number: 20240052042
    Abstract: The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).
    Type: Application
    Filed: December 13, 2021
    Publication date: February 15, 2024
    Inventors: Yuichiro ADACHI, Jennifer R. ALLPORT-ANDERSON, Shaun R. COUGHLIN, John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Alexander Wolfgang KOCH, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia Karola WEZLER, Xiaoling XIE
  • NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230365674
    Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
    Type: Application
    Filed: March 30, 2023
    Publication date: November 16, 2023
    Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
  • NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20220356242
    Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
    Type: Application
    Filed: June 16, 2021
    Publication date: November 10, 2022
    Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20220348651
    Abstract: Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: September 17, 2020
    Publication date: November 3, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
    Publication number: 20220340685
    Abstract: Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.
    Type: Application
    Filed: September 17, 2020
    Publication date: October 27, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • Natriuretic peptide receptor 1 antibodies and methods of use
    Patent number: 11066469
    Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: July 20, 2021
    Assignee: NOVARTIS AG
    Inventors: John Louis Diener, Lars Gadtke, Felix Hartlepp, Kathrin Ladetzki-Baehs, Michael Romanowski, Cesare Russo, Xenia Wezler
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20210155713
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: May 29, 2019
    Publication date: May 27, 2021
    Inventors: Michael DIDONATO, Christoph ERKEL, Anna Galkin, Scott GLASER, Klaus Felix HARTLEPP, Yong JIA, Alexandra KRAUS, Christian Cho-Hua LEE, Sarah Michelle RUE, Jian SHI, Xenia Karola WEZLER
  • ANTI-WT1/HLA-SPECIFIC ANTIBODIES
    Publication number: 20210024635
    Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.
    Type: Application
    Filed: October 13, 2020
    Publication date: January 28, 2021
    Inventors: Andrea MAHR, Toni WEINSCHENK, Dominik MAURER, Claudia WAGNER, Klaus Felix HARTLEPP, Alexandra KRAUS
  • NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20200392225
    Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 17, 2020
    Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
  • COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES
    Publication number: 20200377603
    Abstract: The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.
    Type: Application
    Filed: February 24, 2020
    Publication date: December 3, 2020
    Inventors: Feng Cong, Seth Ettenberg, Felix Hartlepp, Ingo Markus Klagge
  • Anti-WT1/HLA-specific antibodies
    Patent number: 10836829
    Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 17, 2020
    Assignees: IMMATICS BIOTECHNOLOGIES GMBH, MORPHOSYS AG
    Inventors: Andrea Mahr, Toni Weinschenk, Dominik Maurer, Claudia Wagner, Klaus Felix Hartlepp, Alexandra Kraus
  • Compositions and Methods of Use for Therapeutic Low Density Lipoprotein-related protein 6 (LRP6) Antibodies
    Publication number: 20170362326
    Abstract: The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.
    Type: Application
    Filed: March 17, 2016
    Publication date: December 21, 2017
    Applicant: NOVARTIS AG
    Inventors: Feng CONG, Seth ETTENBERG, Felix HARTLEPP, Ingo Markus KLAGGE
  • ANTI-WT1/HLA-SPECIFIC ANTIBODIES
    Publication number: 20170101473
    Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Andrea MAHR, Toni WEINSCHENK, Dominik MAURER, Claudia WAGNER, Felix HARTLEPP, Alexandra KRAUS
  • Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
    Patent number: 9428583
    Abstract: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: August 30, 2016
    Assignee: NOVARTIS AG
    Inventors: Feng Cong, Seth Ettenberg, Felix Hartlepp, Ingo Klagge
  • COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES
    Publication number: 20130058934
    Abstract: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.
    Type: Application
    Filed: May 5, 2011
    Publication date: March 7, 2013
    Applicant: NOVARTIS AG
    Inventors: Feng Cong, Seth Ettenberg, Felix Hartlepp, Ingo Klagge